Jubilant Pharmova gets USFDA nod for Pantoprazole 2026

The regulatory update from Jubilant Pharmova

Jubilant Pharmova has disclosed that its subsidiary chain has received a key US regulatory milestone for a gastrointestinal medicine. The company said Jubilant Generics Limited has received a tentative approval from the US Food and Drug Administration (USFDA) for Pantoprazole Sodium delayed release oral suspension, 40 mg per packet. Jubilant Generics is a subsidiary of Jubilant Pharma Limited, which in turn is a wholly owned subsidiary of Jubilant Pharmova. The company communicated the development through a stock exchange filing dated June 26, noting that the USFDA communication was received on June 25. The approval is tentative, not final, because it is linked to patent protection for the reference product in the US market. Even so, the development signals that the application has cleared scientific and manufacturing review, subject to the remaining legal exclusivity period.

What product got the tentative approval

The product is Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet. Pantoprazole is primarily used to treat gastroesophageal reflux disease (GERD) and to heal acid-related damage to the esophagus. The company highlighted that this is an oral suspension, which is a liquid formulation. Such formats are typically positioned for patients who need an alternative to the standard tablet version. The disclosure identifies the dosage clearly as 40 mg per packet and frames it as a delayed release oral suspension.

What “tentative approval” means in this case

The USFDA’s decision is described as a tentative approval, meaning the product has met regulatory requirements but cannot be commercially launched in the US until certain barriers are removed. In this case, the barrier is the patent covering the currently listed Reference Listed Drug (RLD). Jubilant Pharmova said the tentative approval is subject to the expiry of the RLD patent, expected in December 2026. Final approval is anticipated once that patent expires. This structure is common in US generics, where approvals can be held back until patent or exclusivity periods lapse even after the application is otherwise acceptable.

Patent-linked timeline for a commercial launch

The company has tied the launch timing to the RLD patent expiry. The reference product is expected to remain under patent protection until December 2026, and the company expects full commercial approval after that point. As a result, the milestone is best read as regulatory readiness rather than near-term revenue visibility. Investors tracking the generics pipeline often watch for these patent-dated milestones because they set an outer boundary for when a product can enter the market. Jubilant Pharmova has not provided a specific launch date beyond the December 2026 patent expiry expectation, and it has characterised the next step as final approval after expiry.

Roorkee facility and the pre-approval inspection

Jubilant Pharmova linked the approval to its manufacturing compliance status at the Roorkee site. The company said the tentative approval follows successful completion of the pre-approval inspection (PAI) conducted by the USFDA at the solid dosage manufacturing facility located at Roorkee, Uttarakhand. It also noted that the USFDA had already conducted a pre-approval inspection at the Roorkee facility in August 2025, and that the clearance flows from that visit. The disclosures, taken together, position the Roorkee plant as the manufacturing base supporting the pantoprazole oral suspension approval.

Stock market reaction on June 25

The regulatory update coincided with a move in Jubilant Pharmova’s share price. Shares of Jubilant Pharmova Limited touched Rs 985.95 on June 25 after the company’s arm received the tentative USFDA nod for the antacid drug. The communication from the regulator was received on the same date, according to the company’s filing. While the company did not attribute the stock move to any specific factor beyond the announcement, the timing places the regulatory development at the centre of investor attention for that session.

How this fits into Jubilant’s generics operations

The approval was granted to Jubilant Generics Limited, a subsidiary of Jubilant Pharma Limited, which is wholly owned by Jubilant Pharmova. The company has described the approval as a meaningful regulatory step for its generics business, given that it clears an important checkpoint for a US market product. The product is benchmarked to a US reference listed drug, which is why the patent timeline governs when the approval can convert into a commercial launch. In filings and summaries provided, the company has emphasised compliance and inspection outcomes as the foundation for the milestone.

What changes now for customers and operations

For patients, the disclosure highlights that the approved product is a liquid oral suspension, intended for those who require an alternative to tablets. For operations, the immediate implication is that the product is positioned to move to final approval after the patent expiry. The company’s disclosure does not provide pricing, market size, or expected sales, so the near-term impact is primarily regulatory and strategic. For investors, the most concrete forward marker remains the expected patent expiry in December 2026 and subsequent final approval process.

Key dates and facts at a glance

What to track next

The next concrete catalyst is the expiry of the RLD patent expected in December 2026, after which final approval is anticipated. Investors can also watch for any further company updates on readiness for commercial launch, including supply planning or additional regulatory correspondence. For now, Jubilant Pharmova’s announcement establishes that the application has secured tentative clearance and that the Roorkee manufacturing site has been part of the USFDA review pathway. The company has framed the development as progress toward a future US launch, with the timing anchored to the patent expiry.